Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Saint Louis University Cancer Center /ID# 222287
 (96.5 away) Contact site
  • 835 views
  • 10 Aug, 2022
  • +225 other locations
Featured trial
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …

anemia
Washington University School of Medicine
 (96.3 away) Contact site
  • 12 views
  • 10 Aug, 2022
  • +18 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (UNISUS)

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

left ventricular end-diastolic pressure
septal defect
macitentan
right heart catheterization
hypertension
Washington University School of Medicine
 (96.5 away) Contact site
  • 389 views
  • 23 Jul, 2022
  • +170 other locations
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be …

Washington University Siteman Cancer Center
 (96.3 away) Contact site
  • 147 views
  • 27 Jul, 2022
  • +210 other locations
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

diuretics
right heart catheterization
endothelin receptor antagonist
calcium channel blockers
hypertension
Washington University School of Medicine
 (96.3 away) Contact site
  • 6468 views
  • 05 Jul, 2022
  • +228 other locations
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

generalized myasthenia gravis
Washington University School of Medicine; Department of Neurology
 (96.3 away) Contact site
  • 20 views
  • 11 Aug, 2022
  • +73 other locations
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

medical therapy
Barnes-Jewish Hospital
 (96.3 away) Contact site
  • 422 views
  • 28 Jul, 2022
  • +191 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

invasive bladder cancer
cancer
pembrolizumab
fluorouracil
gemcitabine
Washington University ( Site 0003)
 (96.5 away) Contact site
  • 78 views
  • 11 Aug, 2022
  • +98 other locations
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.

cyst
systolic blood pressure
diastolic blood pressure
Washington University in St. Louis
 (96.3 away) Contact site
  • 341 views
  • 19 Jun, 2022
  • +131 other locations
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy …

carcinoma of oropharynx
squamous cell carcinoma
dental caries
metastasis
ct scan
Washington University School of Medicine ( Site 1800)
 (96.3 away) Contact site
  • 96 views
  • 20 Jul, 2022
  • +131 other locations